E
Can-Fite BioPharma Ltd. CANF
$1.12 $0.0151.36% AMEX
Recommendation
Prev Close
$1.10
Volume
97,877
Avg Vol (90D)
239,463
Market Cap
$16.18M
Dividend & Yield
--
52-Week Range
$1.03 - $4.69
P/E (TTM)
--
EPS (TTM)
-$0.0038
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis
5/5/2025 - Globe Newswire
Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients
4/17/2025 - Globe Newswire
Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares
4/14/2025 - Globe Newswire
Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships
4/14/2025 - Globe Newswire
Can-Fite Reports 2024 Financial Results and Clinical Update
4/14/2025 - Globe Newswire
Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
3/24/2025 - Globe Newswire
Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market
3/20/2025 - Globe Newswire
Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson
3/19/2025 - Globe Newswire
Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient
3/18/2025 - Globe Newswire
Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits
3/3/2025 - Globe Newswire
Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's Namodenoson
2/18/2025 - Globe Newswire
Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25
2/10/2025 - Globe Newswire
Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025
2/5/2025 - Globe Newswire
US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug
1/27/2025 - Globe Newswire
Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug Namodenoson
12/30/2024 - Globe Newswire
8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite's Namodenoson Drug
12/4/2024 - Globe Newswire
Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial
11/11/2024 - Globe Newswire
Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia
11/4/2024 - Globe Newswire
Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson
10/18/2024 - Globe Newswire
FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer
10/9/2024 - Globe Newswire
Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on October 29
10/7/2024 - Globe Newswire
Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis
9/24/2024 - Globe Newswire
Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health
9/16/2024 - Globe Newswire
Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies
8/29/2024 - Globe Newswire
Income Statement
Total Revenue (TTM)
$674.00K
EBITDA (TTM)
-$8.12M
EBIT (TTM)
-$8.13M
Net Income (TTM)
-$7.88M
Balance Sheet
Total Assets (Q)
$9.12M
Total Debt (Q)
$104.00K
Total Liabilities (Q)
$3.68M
Book Value Per Share (Q)
$0.0018
Cash Flow
Cash from Operations (TTM)
-$7.64M
Cash from Investing (TTM)
$1.50M
Cash from Financing (TTM)
$6.71M
Net Change in Cash (TTM)
$547.00K
Filings
Filing Date
Monday, April 14, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of Aug 25 and 29 (est)
Price History
Loading...
Beta
0.79
7-Day Total Return
2.29%
30-Day Total Return
-26.64%
60-Day Total Return
-21.48%
90-Day Total Return
-26.87%
Year to Date Total Return
-37.71%
1-Year Total Return
-44.80%
2-Year Total Return
-45.74%
3-Year Total Return
-86.73%
5-Year Total Return
-93.55%
52-week Low
Apr 30, 2025 - $1.03
52-week High
Jul 22, 2024 - $4.69
Valuation
Market Cap
$16.18M - Nano Cap
Enterprise Value
$8.32M
Price/Sales (TTM)
5,500.00
Price/Book (Q)
611.11
Dividends and Shares
Shares Outstanding
2.53B
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.canfite.com
Phone Number
972 3 924 1114
Address
26 Ben Gurion Street
Ramat Gan, 5257346
Country
Israel
Year Founded
1994
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and... more
AMEX 05/08/2025 3:59PM Eastern Quotes delayed